AU2021358130A1 - Stat degraders and uses thereof - Google Patents
Stat degraders and uses thereof Download PDFInfo
- Publication number
- AU2021358130A1 AU2021358130A1 AU2021358130A AU2021358130A AU2021358130A1 AU 2021358130 A1 AU2021358130 A1 AU 2021358130A1 AU 2021358130 A AU2021358130 A AU 2021358130A AU 2021358130 A AU2021358130 A AU 2021358130A AU 2021358130 A1 AU2021358130 A1 AU 2021358130A1
- Authority
- AU
- Australia
- Prior art keywords
- ring
- nitrogen
- sulfur
- oxygen
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Detergent Compositions (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063088787P | 2020-10-07 | 2020-10-07 | |
| US63/088,787 | 2020-10-07 | ||
| US202063123337P | 2020-12-09 | 2020-12-09 | |
| US63/123,337 | 2020-12-09 | ||
| PCT/US2021/071762 WO2022077010A1 (en) | 2020-10-07 | 2021-10-07 | Stat degraders and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021358130A1 true AU2021358130A1 (en) | 2023-05-18 |
| AU2021358130A9 AU2021358130A9 (en) | 2024-06-27 |
Family
ID=81126142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021358130A Abandoned AU2021358130A1 (en) | 2020-10-07 | 2021-10-07 | Stat degraders and uses thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240293423A1 (https=) |
| EP (1) | EP4225303A4 (https=) |
| JP (1) | JP2023545730A (https=) |
| AU (1) | AU2021358130A1 (https=) |
| CA (1) | CA3194492A1 (https=) |
| IL (1) | IL301830A (https=) |
| MX (1) | MX2023003973A (https=) |
| WO (1) | WO2022077010A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI875749B (zh) | 2019-04-05 | 2025-03-11 | 美商凱麥拉醫療公司 | Stat降解劑及其用途 |
| CN115677831B (zh) * | 2021-07-22 | 2026-03-17 | 杭州和正医药有限公司 | 拟肽类stat降解药物、组合物及应用 |
| EP4499656A1 (en) * | 2022-03-31 | 2025-02-05 | Recludix Pharma, Inc. | Stat modulators and uses thereof |
| WO2024064080A1 (en) * | 2022-09-19 | 2024-03-28 | Kymera Therapeutics, Inc. | Stat6 degraders and uses thereof |
| EP4709370A2 (en) * | 2023-05-09 | 2026-03-18 | Recludix Pharma, Inc. | Stat degraders and uses thereof |
| EP4712974A2 (en) * | 2023-05-15 | 2026-03-25 | Recludix Pharma, Inc. | Stat degraders and uses thereof |
| AU2024334386A1 (en) * | 2023-08-30 | 2026-02-19 | Kymera Therapeutics, Inc. | Stat6 degraders and uses thereof |
| WO2025217647A1 (en) * | 2024-04-12 | 2025-10-16 | Kymera Therapeutics, Inc. | Stat6 degraders and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010077589A2 (en) * | 2008-12-08 | 2010-07-08 | The Regents Of The University Of Michigan Office Of Technology Transfer | Stat3 inhibitors and therapeutic methods using the same |
| MX2020003190A (es) * | 2017-09-22 | 2020-11-11 | Kymera Therapeutics Inc | Degradadores de proteinas y usos de los mismos. |
| CN114269763A (zh) * | 2019-03-26 | 2022-04-01 | 美国密歇根州立大学试剂中心 | Stat3的小分子降解剂 |
-
2021
- 2021-10-07 JP JP2023521335A patent/JP2023545730A/ja active Pending
- 2021-10-07 IL IL301830A patent/IL301830A/en unknown
- 2021-10-07 AU AU2021358130A patent/AU2021358130A1/en not_active Abandoned
- 2021-10-07 MX MX2023003973A patent/MX2023003973A/es unknown
- 2021-10-07 CA CA3194492A patent/CA3194492A1/en active Pending
- 2021-10-07 WO PCT/US2021/071762 patent/WO2022077010A1/en not_active Ceased
- 2021-10-07 EP EP21878728.1A patent/EP4225303A4/en not_active Withdrawn
- 2021-10-07 US US18/030,865 patent/US20240293423A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023545730A (ja) | 2023-10-31 |
| CA3194492A1 (en) | 2022-04-14 |
| EP4225303A4 (en) | 2025-02-19 |
| AU2021358130A9 (en) | 2024-06-27 |
| MX2023003973A (es) | 2023-04-24 |
| EP4225303A1 (en) | 2023-08-16 |
| IL301830A (en) | 2023-06-01 |
| US20240293423A1 (en) | 2024-09-05 |
| WO2022077010A1 (en) | 2022-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7716554B2 (ja) | Stat分解剤およびそれらの使用 | |
| US12521438B2 (en) | SMARCA degraders and uses thereof | |
| WO2020264490A1 (en) | Irak degraders and uses thereof | |
| WO2021127278A1 (en) | Irak degraders and uses thereof | |
| WO2021127283A2 (en) | Irak degraders and uses thereof | |
| WO2020251971A1 (en) | Smarca degraders and uses thereof | |
| WO2020251969A1 (en) | Smarca degraders and uses thereof | |
| WO2020010210A1 (en) | Mertk degraders and uses thereof | |
| EP4121055A1 (en) | Stat degraders and uses thereof | |
| WO2021119159A1 (en) | Irak degraders and uses thereof | |
| EP4081308A1 (en) | Smarca degraders and uses thereof | |
| AU2021358130A9 (en) | Stat degraders and uses thereof | |
| EP4259144A1 (en) | Smarca degraders and uses thereof | |
| WO2022178532A1 (en) | Smarca degraders and uses thereof | |
| WO2022125800A1 (en) | Smarca degraders and uses thereof | |
| EP4543854A1 (en) | Stat degraders and uses thereof | |
| CN116490069A (zh) | Stat降解剂和其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SREP | Specification republished | ||
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |